NCT06132165 2025-11-21
Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
Clinical Trials
13 trialsNCT04730583 2025-02-21
Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT06120036 2025-02-21
Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas
Massachusetts General Hospital
Phase 1 Completed
NCT00608842 2016-01-14
Phase 2 Study for the Treatment of Superficial Lipomas
Kythera Biopharmaceuticals
Phase 2 Completed
NCT01426373 2016-01-14
Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area
Kythera Biopharmaceuticals
Phase 3 Completed
NCT00422188 2015-12-10
Deoxycholic Acid Injection for the Treatment of Superficial Lipomas
Kythera Biopharmaceuticals
Phase 1 Completed
NCT02007434 2015-07-28
Patient Experience Study of Deoxycholic Acid Injection
Kythera Biopharmaceuticals
Phase 3 Completed
NCT00618618 2015-07-14
Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat
Kythera Biopharmaceuticals
Phase 2 Completed
NCT01305577 2015-07-14
Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Kythera Biopharmaceuticals
Phase 3 Completed
NCT01032889 2015-06-15
Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures Study
Kythera Biopharmaceuticals
Phase 2 Completed
NCT01542034 2015-06-15
REFINE-1
Kythera Biopharmaceuticals
Phase 3 Completed
NCT01546142 2015-06-15
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
Kythera Biopharmaceuticals
Phase 3 Completed
NCT01294644 2015-06-12
Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental Fat
Kythera Biopharmaceuticals
Phase 3 Completed